Laura Johnston

Publications

• Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA. Biol Blood Marrow Transplant. 2012; 18 (1): 125-33
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Blood. 2012; 119 (25): 6145-54
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Bone Marrow Transplant. 2012; 47 (4): 581-8
• A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB. Blood. 2011; 118 (15): 4070-8
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Schaenman JM, Shashidhar S, Rhee C, Wong J, Navato S, Wong RM, Ho DY, Arai S, Johnston L, Brown JM. Biol Blood Marrow Transplant. 2011; 17 (5): 693-702
• Long-term clinical course of dry eye in patients with chronic graft-versus-host disease referred for eye examination. Sáles CS, Johnston LJ, Ta CN. Cornea. 2011; 30 (2): 143-9
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Bone Marrow Transplant. 2011; 46 (2): 192-9
• Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG. Bone Marrow Transplant. 2010; 45 (2): 303-9
• Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Biol Blood Marrow Transplant. 2010; 16 (8): 1145-54
• High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. Agarwal R, Dvorak CC, Stockerl-Goldstein KE, Johnston L, Srinivas S. Bone Marrow Transplant. 2009; 43 (7): 547-52
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Johnston L, Best Pract Res Clin Haematol. 2008; 21 (2): 177-92
• High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE. Biol Blood Marrow Transplant. 2006; 12 (7): 703-11
• Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a case report and review of the literature. Cha S, Johnston L, Natkunam Y, Brown J. Transpl Infect Dis. 2005 Sep-Dec; 7 (3-4): 158-61
• CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R. Exp Hematol. 2005; 33 (3): 279-85
• Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R. Blood. 2005; 105 (6): 2300-6
• Protective conditioning for acute graft-versus-host disease. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. N Engl J Med. 2005; 353 (13): 1321-31
• Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ. Biol Blood Marrow Transplant. 2005; 11 (1): 47-55
• Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. Cancer Chemother Pharmacol. 2004; 53 (6): 468-74
• Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma; Steven M Horwitz, Robert S Negrin, Karl G Blume, Sheila Breslin, Monic J Stuart, Keith E Stockerl-Goldstein, Laura J Johnston, Ruby M Wong, Judith A Shizuru, and Sandra J Horning.. Blood. 2003: 2003 1257
• Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, Storb R, Appelbaum FR, Forman SJ, Blume KG, Martin PJ. Blood. 2002; 100 (2): 415-9
• High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Cao TM, Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE. Biol Blood Marrow Transplant. 2001; 7 (5): 294-301